key: cord-1003204-jolav7bz
authors: Blazoski, Cameron; Baram, Michael; Hirose, Hitoshi
title: Outcomes of extracorporeal membrane oxygenation in acute respiratory distress syndrome due to COVID‐19: The lessons learned from the first wave of COVID‐19
date: 2021-03-19
journal: J Card Surg
DOI: 10.1111/jocs.15512
sha: a867b151fc13d1aafe48ac97ca624ddef05f7771
doc_id: 1003204
cord_uid: jolav7bz

INTRODUCTION: Extracorporeal membrane oxygenation (ECMO) has been used as a refractory treatment for acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID‐19), but there has been little evidence of its efficacy. We conducted this study to share our experience using ECMO as a bridge to recovery for ARDS due to COVID‐19. METHODS: All adult patients who were placed on ECMO for ARDS due to COVID‐19 between April 2020 and June 2020 (during the first wave of COVID‐19) were identified. The clinical characteristics and outcomes of these patients were analyzed with a specific focus on the differences between patients who survived to hospital discharge and those who did not. RESULTS: In total, 20 COVID‐19 patients were included in this study. All patients were placed on veno‐veno ECMO. Comparing survivors and non‐survivors, older age was found to be associated with hospital mortality (p = .02). The following complications were observed: renal failure requiring renal replacement therapy (35%, n = 7), bacteremia during ECMO (20%, n = 4), coinfection with bacterial pneumonia (15%, n = 3), cannula site bleeding (15%, n = 3), stroke (10%, n = 2), gastrointestinal bleeding (10%, n = 2), and liver failure (5%, n = 1). The complications associated with patient mortality were culture‐positive septic shock (p = .01), culture‐negative systemic inflammatory response syndrome (p = .01), and renal failure (p = .01). The causes of death were septic shock (44%, n = 4), culture‐negative systemic inflammatory response syndrome (44%, n = 4), and stroke (11%, n = 1). CONCLUSIONS: Based on our experience, ECMO can improve refractory ARDS due to COVID‐19 in select patients. Proper control of bacterial infections during COVID‐19 immunomodulation therapy may be critical to improving survival.

Since its outbreak in 2019, there have been over 50 million cases of coronavirus disease 2019 (COVID-19) and 1.25 million recorded deaths. 1 While most patients experience mild-to-moderate symptoms, COVID-19 can progress to acute respiratory distress syndrome (ARDS), a rapidly progressive inflammatory syndrome that impairs oxygen transport in the lungs. 2, 3 The pulmonary injury in ARDS due to COVID-19 has been shown to resemble ARDS unrelated to COVID-19, and even with mechanical support, ARDS is associated with significant mortality among COVID-19 patients. 2, 4, 5 The high mortality rate of ARDS due to COVID-19 increased the demand for other treatment options, and the use of extracorporeal membrane oxygenation (ECMO) was encouraged for select cases of refractory ARDS with severe hypoxemia. [5] [6] [7] [8] ECMO is a temporary form of mechanical cardiopulmonary support for patients with severe cardiac and/or respiratory shock. First clinically used in 1972, ECMO's use has exponentially increased in the past two decades. [9] [10] [11] While its efficacy in lowering mortality rates is still debated, ECMO is now a common treatment for patients with refractory ARDS. [11] [12] [13] [14] Despite some recent publications, [15] [16] [17] there remains a lack of evidence documenting the overall efficacy of ECMO in treating ARDS due to COVID-19. The purpose of this study is to share our experience using ECMO as a bridge to recovery for patients with ARDS due to COVID-19 during the first wave of the COVID-19 pandemic in our area.

Adult patients positive for COVID-19 who underwent ECMO at our institution from April 1, 2020 to June 11, 2020 were included in this study. Patients were identified by an IRB-approved, prospectively maintained ECMO database (IRB approval: #11D.185). The data from these patients were retrospectively extracted and details were further studied by reviewing medical records. Inclusion criteria included a positive COVID-19 test and a diagnosis of ARDS. ECMO placement was determined by a multidisciplinary team that included a cardiac surgeon, a pulmonary critical care physician, and a cardiovascular intensivist.

The indications for ECMO placement were the same as our previous paper, 18 and contraindications for ECMO placement in treating COVID-19 patients are listed in Table 1 . The exclusion criteria may be more restricted than in non-COVID-19 patients due to the limitations of resources during this pandemic.

The primary mode of ECMO in COVID-19 ARDS was veno-venous ECMO (VV-ECMO) using the femoral and internal jugular veins ( Figure 1 ). All cannulation was performed in the intensive care unit without transport to either the operating room or catheterization lab unless an issue occurred during bedside cannulation. Since Avalon Dual Lumen ECMO Cannula placement always requires fluoroscopy and echocardiography, which requires additional personnel, including radiology technicians and an echocardiography technician, the utilization of the Avalon cannula was discouraged. 18 Veno-arterial ECMO (VA-ECMO) should be reserved for only those who had severe but reversible cardiac dysfunction, such as COVID-19-related myocarditis. ECMO-assisted cardiopulmonary resuscitation for patients with COVID-19 was discouraged due to its known poor outcomes.

Due to the COVID-19 pandemic, we no longer offer a mobile ECMO program outside of our institutional network due to the concern of exposure of required personnel, including the ECMO surgeon, perfusionist, and transfer nurses at the local site. Instead of activating mobile ECMO cannulation teams, we encouraged local cardiac surgeons to place ECMO at their institutions and then transport the patient to our facility.

The general management of ECMO has been described in one of our prior papers. 19 The timing of the decannulation was determined by chest X-ray findings and lung mechanics. Before decannulation, the sweep gas was discontinued for at least 24 h to ensure the lungs were able to exchange oxygen and carbon dioxide appropriately. For COVID-19 cases, we encourage bedside decannulation rather than transporting to the operating room to limit exposure to COVID-19.

The primary endpoints of this study were ECMO survival and hospital survival. ECMO survival was defined by the withdrawal of care or death within 24 h of decannulation. All patients who survived to hospital discharge were classified as "survivors" and all patients who did not survive to hospital discharge were classified as "non-survivors." The baseline characteristics, clinical characteristics, and outcomes were calculated and compared between the two groups.

Data were expressed as the number with percentage, mean ± standard deviation (SD), or median (quantile) as appropriate. Two groups were compared using χ 2 tests for categorical variables and standard t tests for continuous variables as appropriate. Significance was accepted at p < .05. Table 2 . Patients were also treated with different therapies before starting ECMO placement. Therapy was administered in the form of steroids (65%, n = 13), interleukin-6 inhibitors (55%, n = 11), remdesivir (20%, n = 4), and plasma (15%, n = 3). None of the treatment therapies was associated with better or worse mortality rates. The types of treatment and their statistics are displayed in Table 3 .

The ECMO survival rate was (15/20) , and the survival rate to hospital discharge was 55% (11/20). In total, 11 patients were labeled as survivors and 9 as non-survivors based on their survival to hospital discharge. The only baseline characteristic that was statistically different between the two groups was age, as non-survivors were significantly older than survivors (58.4 vs. 49.6; p = .02).

The causes of death were septic shock (44%, n = 4), culture-negative systemic inflammatory response syndrome (SIRS) (44%, n = 4), and stroke (11%, n = 1). The most common complication observed was renal failure requiring renal replacement therapy (35%, n = 7). Complications that were associated with patient mortality between the two groups were blood culture-positive sepsis (p = .01), culture-negative SIRS (p = .01), cannula site bleeding (p = .04), and renal failure (p = .01). The complications are displayed in Table 4 .

The primary finding of this study is that among the 20 COVIDpositive patients that we treated with ECMO, the survival rate to hospital discharge was 55%. Also, our results suggest that proper patient selection and control of bacterial infections before and/or during ECMO placement may be key to improving survival, as culture-positive septic shock and culture-negative SIRS were the main causes of death and were only observed in patients who failed to survive to hospital discharge.

Patients were primarily cannulated via the right internal jugular vein and right femoral vein due to anatomical preference

The treatment of ARDS with ECMO remains disputed even though its use in treating ARDS has increased in the past decade. 11, 12 While the exact mortality rate of treating ARDS with ECMO varies by research study, it is generally accepted to range between 34% and 39%. 11,13,14 Thus, it is generally recognized that ECMO should be primarily used for refractory cases of ARDS, in which a patient remains severely hypoxic despite aggressive treatment. 12 Interestingly, our study and others on COVID-19 have found that the mortality rates of treating ARDS due to COVID-19 with ECMO are similar to the previously reported mortality rates of treating non-COVID T A B L E 2 Demographics and baseline characteristics of studied patients January 16th to May 1st of 2020. Another study that more closely resembles our own is from Schmidt et al., 16 who documented the outcomes of 83 COVID-positive patients who were treated at their hospital.

They discovered that the 60-day mortality of these patients was 31%.

Compared with these studies, our patients had a slightly higher mortality rate of 45%; however, it should be noted that our sample size was significantly smaller than either of these two articles.

Based on this current research on the use of ECMO in ARDS due to COVID-19, the mortality rate appears to be anywhere between 31% and 45%. This mortality rate is similar to the 34%-39% mortality rate in treating non-COVID ARDS with ECMO in select patients. Therefore, it is possible that ECMO is just as effective at treating ARDS due to Our study is limited by its small sample size and being based in one hospital center. It is also possible that there was selection bias in this study, even though ECMO placement was determined by a multidisciplinary team of physicians.

Despite its limitations, this study provides extensive data on 20 patients with ARDS due to COVID-19 who were treated with ECMO.

While we cannot extrapolate from a sample size of 20 patients, we hope our evidence can complement other studies and contribute to meaningful meta-analyses and statistical analyses. Cases of ARDS due to COVID-19

will continue in the coming months and years, and we hope that our analysis contributes to the growing research on how to treat this deadly disease.

Based on our results, we conclude that ECMO placement can improve refractory cases of ARDS due to COVID-19. More research is needed to better understand the true efficacy of ECMO in treating COVID-19 and the mortality rate associated with it.

WHO.Coronavirus Disease (COVID-19) Dashboard

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

Initial ELSO Guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure

Clinical management of COVID-19

Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

The role of ECMO in COVID-19: can it provide rescue therapy in those who are critically ill?

Extracorporeal membrane oxygenation for treating severe cardiac and respiratory disease in adults: part 1-overview of extracorporeal membrane oxygenation

The role and impact of extracorporeal membrane oxygenation in critical care

Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis

Extracorporeal membrane oxygenation for ARDS in adults

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome. An international multicenter prospective cohort

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Role of extracorporeal membrane oxygenation in COVID-19: a systematic review

Veno-venous extracorporeal membrane oxygenation (VV ECMO): indications, preprocedural considerations, and technique

Issues in the intensive care unit for patients with extracorporeal membrane oxygenation

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Outcomes of extracorporeal membrane oxygenation in acute respiratory distress syndrome due to COVID-19: the lessons learned from the first wave of COVID-19

The authors declare that there are no conflict of interests.

https://orcid.org/0000-0001-5210-810X